Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

The rational design of PROTACs is difficult due to their obscure structure-activity
relationship. This study introduces a deep neural network model-DeepPROTACs to help …

Targeted protein degradation using the PROTAC technology is emerging as a novel
therapeutic method to address diseases driven by the aberrant expression of a disease …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Increased androgen receptor (AR) activity drives therapeutic resistance in advanced
prostate cancer. The most common resistance mechanism is amplification of this locus …

Prostate cancer is the second-leading cause of cancer-related mortality in men in Western
societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer …

Lysine-specific histone demethylase 1 (LSD1) represents the first example of an identified
nuclear protein with histone demethylase activity. In particular, it plays a special role in the …

Understanding the mechanisms of androgen receptor (AR) activation in the milieu of low
androgen is critical to effective treatment of castration-resistant prostate cancer (CRPC) …

Dysregulation of histone lysine methyltransferases and demethylases is one of the major
mechanisms driving the epigenetic reprogramming of transcriptional networks in castration …